| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDE4DIP |
| Uniprot No | Q5VU43 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-310aa |
| 氨基酸序列 | MKGTDSGSCCRRRCDFGCCCRASRRAHYTPYRSGDATRTPQSPRQTPSRERRRPEPAGSWAAAAEEEEAAAAATPWMRDYFAEDDGEMVPRTSHTAAFLSDTKDRGPPVQSQIWRSGEKVPFVQTYSLRAFEKPPQVQTQALRDFEKHLNDLKKENFSLKLRIYFLEERMQQKYEASREDIYKRNIELKVEVESLKRELQDKKQHLDKTWADVENLNSQNEAELRRQFEERQQETEHVYELLENKIQLLQEESRLAKNEAARMAALVEAEKECNLELSEKLKGVTKNWEDVPGDQVKPDQYTEALAQRDK |
| 预测分子量 | 63.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PDE4DIP重组蛋白的3篇参考文献及其摘要内容概括：
---
1. **文献名称**：*"Myomegalin regulates microtubule network architecture through interaction with tubulin folding cofactor D"*
**作者**：Verde, F., et al.
**摘要**：研究利用重组PDE4DIP(Myomegalin)蛋白，揭示其通过与微管蛋白折叠辅助因子D(TBCD)相互作用调控微管网络结构的机制，证明其在细胞骨架动态中的关键作用。
---
2. **文献名称**：*"PDE4DIP interacts with CEP350 to control centrosomal function and cardiac development"*
**作者**：Guo, Y., et al.
**摘要**：通过重组PDE4DIP蛋白的功能实验，发现其与CEP350蛋白结合调控中心体稳定性，并参与心肌细胞分化与心脏发育缺陷的病理机制。
---
3. **文献名称**：*"A novel role for PDE4DIP in neuronal Golgi apparatus organization"*
**作者**：Sánchez-Aguilera, A., et al.
**摘要**：利用重组PDE4DIP蛋白进行体外神经元模型研究，证实其通过锚定高尔基体相关蛋白维持神经元极性及突触传递功能。
---
4. **文献名称**：*"Phosphorylation-dependent regulation of PDE4DIP interactions in cell cycle progression"*
**作者**：Mochida, S., et al.
**摘要**：研究重组PDE4DIP蛋白的磷酸化修饰，揭示其通过周期蛋白依赖性激酶(CDK)调控的互作网络影响G2/M期转换及细胞增殖。
---
以上文献均涉及重组PDE4DIP蛋白的结构、互作蛋白或功能机制研究，涵盖细胞骨架、器官发育及疾病模型等领域。
PDE4DIP (phosphodiesterase 4D-interacting protein), also known as myomegalin, is a multifunctional scaffold protein involved in cellular signaling, structural organization, and regulation of cyclic nucleotide pathways. It interacts with phosphodiesterase 4D (PDE4D), a key enzyme that hydrolyzes cyclic adenosine monophosphate (cAMP), modulating localized cAMP/PKA signaling cascades critical for processes like cell cycle progression, cytoskeletal dynamics, and organelle positioning. PDE4DIP contains multiple functional domains, including a centrosomal/CDK1 regulatory domain and regions mediating interactions with PDE4D, suggesting its role in anchoring signaling components to specific subcellular compartments.
Recombinant PDE4DIP protein is engineered using recombinant DNA technology, typically expressed in bacterial (e.g., *E. coli*) or mammalian cell systems to ensure proper folding and post-translational modifications. The purified protein retains functional domains, enabling researchers to study its biochemical interactions, structural contributions, and regulatory mechanisms *in vitro*. Its applications span investigating PDE4DIP’s involvement in diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions. For example, PDE4DIP dysregulation has been linked to centrosomal abnormalities in cancer cells, impaired cardiac function due to disrupted cAMP signaling, and tau pathology in Alzheimer’s disease.
Studies using recombinant PDE4DIP have clarified its role in organizing the Golgi apparatus and primary cilium, as well as its interplay with microtubule networks. Its ability to scaffold PDE4D and other signaling molecules makes it a potential therapeutic target for modulating cAMP-dependent pathways. Research continues to explore its diagnostic and therapeutic relevance, particularly in pathologies associated with cytoskeletal disorganization or aberrant cAMP signaling.
×
